EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)

Quanying Tang, Shikang Zhao, Ning Zhou, Jinling He, Lingling Zu, Tingwen Liu, Zuoqing Song, Jun Chen, Ling Peng, Song Xu

International Journal of Oncology · 01.03.2023 · 62 (4)

DOI: 10.3892/ijo.2023.5497 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Oncology, online erschienen am 01.03.2023. Verfasst von Quanying Tang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoadjuvant Therapy, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A comprehensive search regarding programmed cell death protein 1 (PD‑1)/programmed death‑ligand 1 (PD‑L1) inhibitor monotherapy or combination therapy in neoadjuvant settings of 11 types of solid cancer was performed using the PubMed, Cochrane and Embase databases, and the abstracts of various conferences were screened. Data presented in 99 clinical trials indicated that preoperative treatment with PD‑1/PD‑L1 combined therapy, particularly immunotherapy plus chemotherapy, could achieve a higher objective response rate, a higher major pathologic response rate and a higher pathologic complete response rate, as well as a lower number of immune‑related adverse events compared with PD‑1/PD‑L1 monotherapy or dual immunotherapy. Although PD‑1/PD‑L1 inhibitor combination caused more treatment‑related adverse events (TRAEs) in patients, most of the TRAEs were acceptable and did not cause marked delays in operation. The data suggest that patients with pathological remission after neoadjuvant immunotherapy exhibit improved postoperative disease‑free survival compared with those without pathological remission. Further studies are still required to evaluate the long‑term survival benefit of neoadjuvant immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoadjuvant TherapyNeoplasmsHumansB7-H1 AntigenProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

MPRORRclinical trialsneoadjuvant therapypCRprogrammed cell death protein 1/programmed death‑ligand 1solid tumor

Substanzen

B7-H1 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China.
  • Department of Respiratory Disease, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310000, P.R. China.

Zitieren

APA

Tang, Q., Zhao, S., Zhou, N., He, J., Zu, L., Liu, T., Song, Z., Chen, J., Peng, L., & Xu, S. (2023). PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review). International Journal of Oncology, 62(4). https://doi.org/10.3892/ijo.2023.5497

Vancouver

Tang Q, Zhao S, Zhou N, He J, Zu L, Liu T, et al. PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review). International Journal of Oncology. 2023;62(4). doi:10.3892/ijo.2023.5497

BibTeX
@article{Tang2023,
  author = {Tang, Quanying and Zhao, Shikang and Zhou, Ning and He, Jinling and Zu, Lingling and Liu, Tingwen and Song, Zuoqing and Chen, Jun and Peng, Ling and Xu, Song},
  title = {PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)},
  journal = {International Journal of Oncology},
  year = {2023},
  volume = {62},
  number = {4},
  doi = {10.3892/ijo.2023.5497}
}
Kostenlos starten →